According to a recent study published online in the journal Annals of Oncology, researchers have found that trametinib, a selective allosteric MEK1/MEK2 inhibitor, showed similar progression-free survival and response rate as docetaxel in patients with previously treated KRAS mutation-positive non-small cell lung cancer (NSCLC).

For the phase II study, researchers sought to compare trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy.

They enrolled 129 patients withKRAS-mutant NSCLC and randomly assigned them 2:1 to receive trametinib 2mg orally once daily or docetaxel 75mg/m2 IV every 3 weeks.

Continue Reading

RELATED: Tecemotide May Be Effective in NSCLC with Concurrent Chemoradiotherapy

Results showed that the median progression-free survival was 12 weeks in the trametinib group and 11 weeks in the docetaxel group (HR = 1.14; 95% CI: 0.75 – 1.75; P = 0.5197).

Although the overall survival data are immature, the median overall survival thus far was 8 months in the trametinib group and was not reached in the docetaxel group (HR = 0.97; 95% CI: 0.52 – 1.83; P = 0.934).

Twelve percent of patients in the trametinib arm achieved partial responses compared with 12% in the docetaxel arm (P = 1.0000).


  1. Blumenschein G, Smit EF, Planchard D, et al. A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung cancer (NSCLC).Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv072.